Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825377 | 0.79 | UGT2B17 (0.57) | UGT2B17KDM4CSIGMAR1 | |
| SCHEMBL15286569 | 0.79 | UGT2B17 (0.62) | UGT2B17KDM4CSIGMAR1 | |
| SCHEMBL5173559 | 0.78 | UGT2B17 (0.60) | UGT2B17KDM4CSIGMAR1 | |
| SCHEMBL13229181 | 0.77 | ACHE (0.38) | KMT2A | |
| SCHEMBL15287102 | 0.76 | UGT2B17 (0.57) | UGT2B17KDM4CSIGMAR1KMT2A | |
| SCHEMBL5482952 | 0.74 | UGT2B17 (0.46) | UGT2B17KDM4C | |
| SCHEMBL15286607 | 0.74 | KDM4C (0.52) | UGT2B17KDM4CSIGMAR1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1976240 | 0.71 | UGT2B17 (0.61) | UGT2B17KDM4CSIGMAR1 | |
| SCHEMBL5474630 | 0.71 | UGT2B17 (0.51) | UGT2B17KDM4CSIGMAR1 | |
| SCHEMBL5272877 | 0.69 | UGT2B17 (0.62) | UGT2B17KDM4CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869013-A1 | SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| WO-2006108711-A1 | SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | UGT2B17 500/4885KDM4C 3261/4885SIGMAR1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.